Abstract
Revascularization remains the cornerstone of managing obstructive coronary artery disease. Although percutaneous coronary interventions involving the insertion of metal scaffolds, known as stents, has emerged as the preferred method of restoring vessel patency, as many as 30% of patients will experience a gradual re-narrowing of the lumen caused by neointima (NI) formation, resulting in a condition known as in-stent restenosis (ISR). ISR represents a significant limitation to percutaneous revascularization – however, abrogating NI formation following stent implantation has been hampered by an incomplete understanding of the pathogenesis of in-stent lesions. While numerous mechanisms have been proposed to explain the pathogenesis of ISR, data from human and animal models have yielded conflicting results. Herein, we review key studies of NI development following vascular injury with a focus on the origin of cells participating in NI formation.
Keywords: In-stent restenosis, neointima, smooth muscle cell, endothelial cell, vascular progenitor cell, endothelial progenitor cell, drug-eluting stents, hyperplasia, contractile phenotype
Cardiovascular & Hematological Disorders-Drug Targets
Title: Pathogenesis of Neointima Formation Following Vascular Injury
Volume: 11 Issue: 1
Author(s): Ali Pourdjabbar, Benjamin Hibbert, Trevor Simard and Xiaoli Ma
Affiliation:
Keywords: In-stent restenosis, neointima, smooth muscle cell, endothelial cell, vascular progenitor cell, endothelial progenitor cell, drug-eluting stents, hyperplasia, contractile phenotype
Abstract: Revascularization remains the cornerstone of managing obstructive coronary artery disease. Although percutaneous coronary interventions involving the insertion of metal scaffolds, known as stents, has emerged as the preferred method of restoring vessel patency, as many as 30% of patients will experience a gradual re-narrowing of the lumen caused by neointima (NI) formation, resulting in a condition known as in-stent restenosis (ISR). ISR represents a significant limitation to percutaneous revascularization – however, abrogating NI formation following stent implantation has been hampered by an incomplete understanding of the pathogenesis of in-stent lesions. While numerous mechanisms have been proposed to explain the pathogenesis of ISR, data from human and animal models have yielded conflicting results. Herein, we review key studies of NI development following vascular injury with a focus on the origin of cells participating in NI formation.
Export Options
About this article
Cite this article as:
Pourdjabbar Ali, Hibbert Benjamin, Simard Trevor and Ma Xiaoli, Pathogenesis of Neointima Formation Following Vascular Injury, Cardiovascular & Hematological Disorders-Drug Targets 2011; 11 (1) . https://dx.doi.org/10.2174/187152911795945169
DOI https://dx.doi.org/10.2174/187152911795945169 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effect of Aging on Metabolic Pathways in Endothelial Progenitor Cells
Current Pharmaceutical Design Effects of Different Process and Machine Parameters on Physical Properties of Rice Flour, Corn Flour and Deoiled Rice Bran Extruded Product
Current Nutrition & Food Science A Review of Chinese Herbal Medicine for the Treatment of Chronic Heart Failure
Current Pharmaceutical Design Metabolic Features Across the Female Life Span in Women with PCOS
Current Pharmaceutical Design Pro-Angiogenic Effect of Endomyocardial Biopsy-Derived Cells for Cardiac Regeneration
Current Tissue Engineering (Discontinued) Discovery Approaches for Novel Dyslipidemia Drugs
Current Drug Discovery Technologies A Rationale for Combined Therapy with a Calcium Channel Blocker and a Statin: Evaluation of Basic and Clinical Evidence
Current Drug Targets - Cardiovascular & Hematological Disorders Drug Repurposing: An Emerging Tool for Drug Reuse, Recycling and Discovery
Current Drug Research Reviews Conivaptan: Potential Therapeutic Implications in Heart Failure
Recent Patents on Cardiovascular Drug Discovery Algorithms and Criteria for Transcatheter Aortic Valve Replacement Patient Selection: Current Status and Future Trends
Current Pharmaceutical Design Withdrawal Notice: Design and Analysis of Optimization and Tuning in Data Warehouses Using Bitmap Indexes
Recent Advances in Computer Science and Communications Novel Molecular Targets in the Treatment of Cardiac Hypertrophy
Recent Patents on Cardiovascular Drug Discovery Opportunities and Challenges for Host-Directed Therapies in Tuberculosis
Current Pharmaceutical Design Modulation of Retinal Arteriolar Central Reflection by APOE Genotype
Current Alzheimer Research Smoking and Hypertension: Independent or Additive Effects to Determining Vascular Damage?
Current Vascular Pharmacology New Generation Calcium Channel Blockers in Hypertensive Treatment
Current Hypertension Reviews Retracted: Junk Food Consumption, Perceptions and Associated Factors among the Private School Children
Current Nutrition & Food Science An Apple Plus a Brazil Nut a Day Keeps the Doctors Away: Antioxidant Capacity of Foods and their Health Benefits
Current Pharmaceutical Design Acute Coronary Syndromes as Auto-Inflammatory Disorders
Current Pharmaceutical Design Alzheimer’s Disease and Environmental Exposure to Lead: The Epidemiologic Evidence and Potential Role of Epigenetics
Current Alzheimer Research